Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Rationale and design of the EU-CERT-ICD prospective study: comparative effectiveness of prophylactic ICD implantation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Lung diffusion capacity in advanced heart failure: relation to central haemodynamics and outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Markus Zabel
  • Christian Sticherling
  • Rik Willems
  • Andrzej Lubinski
  • Axel Bauer
  • Leonard Bergau
  • Frieder Braunschweig
  • Josep Brugada
  • Sandro Brusich
  • David Conen
  • Iwona Cygankiewicz
  • Panagiota Flevari
  • Milos Taborsky
  • Jim Hansen
  • Gerd Hasenfuß
  • Robert Hatala
  • Heikki V Huikuri
  • Svetoslav Iovev
  • Stefan Kääb
  • Gabriela Kaliska
  • Jaroslaw D Kasprzak
  • Lars Lüthje
  • Marek Malik
  • Tomas Novotny
  • Nikola Pavlović
  • Georg Schmidt
  • Tchavdar Shalganov
  • Rajeeva Sritharan
  • Simon Schlögl
  • Janko Szavits Nossan
  • Vassil Traykov
  • Anton E Tuinenburg
  • Vasil Velchev
  • Marc A Vos
  • Stefan N Willich
  • Tim Friede
  • Jesper Hastrup Svendsen
  • Béla Merkely
  • EU-CERT-ICD Study Investigators
Vis graf over relationer

AIMS: The clinical effectiveness of primary prevention implantable cardioverter defibrillator (ICD) therapy is under debate. The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators (EU-CERT-ICD) aims to assess its current clinical value.

METHODS AND RESULTS: The EU-CERT-ICD is a prospective investigator-initiated non-randomized, controlled, multicentre observational cohort study performed in 44 centres across 15 European Union countries. We will recruit 2250 patients with ischaemic or dilated cardiomyopathy and a guideline indication for primary prophylactic ICD implantation. This sample will include 1500 patients at their first ICD implantation and 750 patients who did not receive a primary prevention ICD despite having an indication for it (non-randomized control group). The primary endpoint is all-cause mortality; the co-primary endpoint in ICD patients is time to first appropriate shock. Secondary endpoints include sudden cardiac death, first inappropriate shock, any ICD shock, arrhythmogenic syncope, revision procedures, quality of life, and cost-effectiveness. At baseline (and prior to ICD implantation if applicable), all patients undergo 12-lead electrocardiogram (ECG) and Holter ECG analysis using multiple advanced methods for risk stratification as well as detailed documentation of clinical characteristics and laboratory values. Genetic biobanking is also organized. As of August 2018, baseline data of 2265 patients are complete. All subjects will be followed for up to 4.5 years.

CONCLUSIONS: The EU-CERT-ICD study will provide a necessary update about clinical effectiveness of primary prophylactic ICD implantation. This study also aims for improved risk stratification and patient selection using clinical and ECG risk markers.

TidsskriftESC Heart Failure
Udgave nummer1
Sider (fra-til)182-193
Antal sider12
StatusUdgivet - 1 feb. 2019

Bibliografisk note

© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

ID: 56979200